An in vivo CRISPR gene-editing therapy receives broad regulatory approval for a common non-rare disease before

Question

Six frontier AI models put this at 17% by 26 Sept 2031. Full reasoning from every model.

WillHappen.ai · Accepted Answer

17% — the median of 6 frontier models, resolving by 2031-09-26.

Answer

Gemini (Google): 8% — Cardiovascular outcome trials require thousands of patients and multi-year follow-up, which cannot conclude and clear the FDA by 2030. Leading in vivo candidates like Verve's PCSK9 editor are testing in familial hypercholesterolemia before expanding to broad ASCVD. FDA safety hurdles for permanent edits are exceptionally high when cheap, non-permanent alternatives like statins exist. A rapid surrogate-biomarker Phase 3 approval for a wide non-rare indication by late 2029 would require unprecedented regulatory leeway.

Answer

Claude (Anthropic): 8% — Depends on whether an in vivo CRISPR trial (e.g., NTLA-2001 for ATTR, or lipid-lowering programs) reaches Phase 3 approval by 2030 for a common indication. Current in vivo CRISPR programs like Intellia's NTLA-2001 (ATTR amyloidosis) and Verve's VERVE-102 (cholesterol) are still in Phase 1/2/3 as of 2025-26, leaving little… Typical Phase 3 completion plus FDA review takes 4-6 years from current stage, and ATTR/cholesterol indications may not qualify as 'common non-rare disease' depending on… A surprise accelerated approval pathway or breakthrough designation for a cardiovascular/metabolic in vivo CRISPR therapy would be the main upside catalyst to watch.

Answer

GPT (OpenAI): 29% — The key hinge is whether late-stage in vivo editing can show durable benefit and an acceptable safety margin in large populations. FDA or EMA must approve a CRISPR editor for a prevalent indication by 26 September 2031, after pivotal trials and manufacturing review. The closest programs, including Verve’s cardiovascular editors and Intellia’s in-vivo candidates, still need durable efficacy and off-target safety data. No in-vivo CRISPR product has yet cleared FDA or EMA; a successful Phase 3 cardiovascular program by 2029 would sharply raise the odds.

Answer

Grok (xAI): 38% — Lead in-vivo CRISPR programs for prevalent indications must finish pivotal trials and gain FDA/EMA approval by end-2029. Verve/Lilly PCSK9 base editors are farthest along; a Phase 3 start by mid-2027 is required to file before 2030. Novel gene-therapy Ph2-to-approval success is ~25% over 5+ years; this case is modestly higher on efficacy but lower on in-vivo safety and CVOT size. Clean late-stage LDL-C/safety data would raise odds sharply; a hold or rare-disease-only first approvals would drop them.

Answer

DeepSeek (DeepSeek): 22% — In vivo CRISPR for a common disease needs a pivotal trial readout plus a filing, and neither exists yet. No in vivo CRISPR candidate for a prevalent condition has completed a pivotal Phase 3; most are in Phase 1/2 as of late 2026. FDA/EMA review alone takes 10-12 months after filing, so a filing must land by mid-2030 to clear the deadline. Base rate for a first-in-class modality jumping from Phase 2 to broad approval in under four years is low, well under 25%.

Answer

Qwen (Alibaba): 12% — No in vivo CRISPR candidate for a common disease has cleared Phase III with a clear regulatory path as of late 2026. Verve (VERVE-101 for PCSK9/heart disease) and Intellia (NTLA-2001 for ATTR) are the furthest along, but both target relatively narrow indications, not truly common… Even if Phase III data lands in 2027-2028, FDA/EMA review timelines of 12-18 months plus potential advisory committee hurdles make pre-2030 approval extremely tight. The base rate for novel-modality therapies moving from Phase II to approval in under 4 years is low (~10-15%), and no in vivo CRISPR product has yet demonstrated the…

An in vivo CRISPR gene-editing therapy receives broad regulatory approval for a common non-rare disease before 2030.

What each one said

An in vivo CRISPR gene-editing therapy receives broad regulatory approval for a common non-rare disease before 2030.

A gene therapy targeting herpes simplex virus enters Phase 3 clinical trials before 2029.

The FDA approves at least 10 novel gene therapies in a single calendar year before 2030.

A clinical trial begins treating human embryos with heritable germline gene editing before 2035.

LambdaVision begins clinical trials for its microgravity-assembled retinal implant by December 31, 2028.